158 related articles for article (PubMed ID: 12599236)
1. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
[TBL] [Abstract][Full Text] [Related]
2. Rise of oligodendroglioma hypermutator phenotype from a subclone harboring TP53 mutation after TMZ treatment.
Higuchi F; Uzuka T; Matsuda H; Sumi T; Iwata K; Namatame T; Shin M; Akutsu H; Ueki K
Brain Tumor Pathol; 2024 Apr; 41(2):80-84. PubMed ID: 38294664
[TBL] [Abstract][Full Text] [Related]
3. Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.
Sasaki H; Kitamura Y; Toda M; Hirose Y; Yoshida K
Brain Tumor Pathol; 2024 Apr; 41(2):43-49. PubMed ID: 38564040
[TBL] [Abstract][Full Text] [Related]
4. High Radiation Dose to the Fornix Causes Symptomatic Radiation Necrosis in Patients with Anaplastic Oligodendroglioma.
Kim TH; Cho J; Kang SG; Moon JH; Suh CO; Park YW; Chang JH; Yoon HI
Yonsei Med J; 2024 Jan; 65(1):1-9. PubMed ID: 38154474
[TBL] [Abstract][Full Text] [Related]
5. T2-FLAIR mismatch sign correlates with
Ebiko Y; Tamura K; Hara S; Inaji M; Tanaka Y; Nariai T; Ishii K; Maehara T
J Neurooncol; 2023 Aug; 164(1):257-265. PubMed ID: 37589920
[TBL] [Abstract][Full Text] [Related]
6. Generation of chromosome 1p/19q co-deletion by CRISPR/Cas9-guided genomic editing.
Li C; Liu Z; Zhang X; Wang H; Friedman GK; Ding Q; Zhao X; Li H; Kim K; Yu X; Burt Nabors L; Han X; Zhao R
Neurooncol Adv; 2022; 4(1):vdac131. PubMed ID: 36225650
[TBL] [Abstract][Full Text] [Related]
7. Evaluation Criteria for Chromosome Instability Detection by FISH to Predict Malignant Progression in Premalignant Glottic Laryngeal Lesions.
Bergshoeff VE; Balkenhol MCA; Haesevoets A; Ruland A; Chenault MN; Nelissen RC; Peutz CJ; Clarijs R; Van der Laak JAWM; Takes RP; Van den Brekel MW; Van Velthuysen MF; Ramaekers FCS; Kremer B; Speel EM
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805032
[TBL] [Abstract][Full Text] [Related]
8. Can Apparent Diffusion Coefficient Predict the Grade, Genotype, or Proliferation Index of Oligodendrogliomas.
Ali LA; Usman KM; Fatima M; Amna A; Saeed AT; Qadeer SN; Shahzad SM; Ather ES
Asian J Neurosurg; 2021; 16(4):752-758. PubMed ID: 35071073
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological analysis of T2-FLAIR mismatch sign in lower-grade gliomas.
Deguchi S; Oishi T; Mitsuya K; Kakuda Y; Endo M; Sugino T; Hayashi N
Sci Rep; 2020 Jun; 10(1):10113. PubMed ID: 32572107
[TBL] [Abstract][Full Text] [Related]
10. Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma.
Nauen DW; Guajardo A; Haley L; Powell K; Burger PC; Gocke CD
Converg Sci Phys Oncol; 2015 Sep; 1(1):. PubMed ID: 31602317
[TBL] [Abstract][Full Text] [Related]
11. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: A SEER-based analysis.
Dong X; Noorbakhsh A; Hirshman BR; Zhou T; Tang JA; Chang DC; Carter BS; Chen CC
Neurooncol Pract; 2016 Mar; 3(1):29-38. PubMed ID: 31579519
[TBL] [Abstract][Full Text] [Related]
12. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
13. Genotyping low-grade gliomas among Hispanics.
Cardona AF; Rojas L; Wills B; Behaine J; Jiménez E; Hakim F; Useche N; Bermúdez S; Arrieta O; Mejía JA; Ramón JF; Carranza H; Vargas C; Otero J; González D; Rodríguez J; Ortiz LD; Cifuentes H; Balaña C
Neurooncol Pract; 2016 Sep; 3(3):164-172. PubMed ID: 31386063
[TBL] [Abstract][Full Text] [Related]
14. Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma.
Ruff MW; Buckner JC; Johnson DR; van den Bent MJ; Geurts M
Neurooncol Pract; 2019 Jan; 6(1):17-21. PubMed ID: 31386006
[TBL] [Abstract][Full Text] [Related]
15. Current therapeutic approaches to diffuse grade II and III gliomas.
Picca A; Berzero G; Sanson M
Ther Adv Neurol Disord; 2018; 11():1756285617752039. PubMed ID: 29403544
[TBL] [Abstract][Full Text] [Related]
16. Regional specificity of 1p/19q co-deletion combined with radiological features for predicting the survival outcomes of anaplastic oligodendroglial tumor patients.
Wang K; Wang Y; Fan X; Li Y; Liu X; Wang J; Ai L; Dai J; Jiang T
J Neurooncol; 2018 Feb; 136(3):523-531. PubMed ID: 29230668
[TBL] [Abstract][Full Text] [Related]
17. Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications.
Malta TM; de Souza CF; Sabedot TS; Silva TC; Mosella MS; Kalkanis SN; Snyder J; Castro AVB; Noushmehr H
Neuro Oncol; 2018 Apr; 20(5):608-620. PubMed ID: 29036500
[TBL] [Abstract][Full Text] [Related]
18. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
19. Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report.
Achey RL; Khanna V; Ostrom QT; Kruchko C; Barnholtz-Sloan JS
J Neurooncol; 2017 May; 133(1):17-25. PubMed ID: 28397028
[TBL] [Abstract][Full Text] [Related]
20. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
Lassman AB
CNS Oncol; 2015; 4(5):341-6. PubMed ID: 26544062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
